The Phase 2 Cliff: 173 AI Drug Programs in Trials, Zero Approvals, and What the Numbers Actually Prove - August 4, 2026

The Phase 2 Cliff: 173 AI Drug Programs in Trials, Zero Approvals, and What the Numbers Actually Prove AI discovered molecules clear Phase 1 trials at 80 to 90 percent, far above the historical industry baseline. Then they hit Phase 2 and success collapses to roughly 40 percent, statistically indistinguishable from conventionally discovered drugs. Chris and Laura dig into what that cliff reveals: AI solved the chemistry, not the biology. Featuring Insilico's rentosertib, the first molecule w...